# DESCRIPTION

## BACKGROUND

- introduce C. trachomatis
- describe STI statistics
- discuss limitations of antibiotic treatment
- highlight importance of vaccine development
- describe role of CD4+ T-cells in infection resolution
- discuss Th1 cell-mediated response
- describe antibody responses
- discuss MOMP as a vaccine candidate
- highlight need for mucosal vaccine

## SUMMARY

- summarize methods for treating/preventing Chlamydial infection
- summarize pharmaceutical compositions and immunization methods

## DETAILED DESCRIPTION

- introduce Chlamydia vaccines
- describe vault structure
- detail vault composition
- describe MVP protein
- describe VPARP protein
- describe TEP1 protein
- describe vRNA molecules
- provide embodiment of vault-like particle
- provide embodiment of vault-like particle as carrier molecule
- describe vaccine compositions
- describe immunogenic peptides
- describe MOMP protein
- describe fragments of MOMP
- describe variants of immunogenic peptides
- describe homologous proteins
- describe methods for identifying homologues
- describe vaccine compositions for mucosal surfaces
- describe cell-mediated immune response
- describe antibody immune response
- define protective immunity
- define active immune response
- define passive immunity
- describe theory of vault-like particles enhancing immunogenicity
- describe advantages of vault-like particles
- provide method of using vaults as carrier molecules
- provide method of delivering substances to organisms or tissues
- provide method of delivering substances to environmental medium
- describe targeting moiety on vault-like particles
- describe Fc binding domain
- provide method of treating or preventing Chlamydia infection
- provide method of reducing disease or condition caused by Chlamydia
- provide method of immunizing against Chlamydia infection
- provide method of reducing infertility due to Chlamydia
- provide method of eliciting immune response against Chlamydia
- provide method of preventing damage by substances
- define MVP without VPARP, TEP1 and vRNA
- define MVP with VPARP or TEP1 or vRNA
- define modified MVP
- define human
- define organism, tissue and cell
- define environmental medium
- define administering
- define dosage
- define MS2
- define comprise
- describe method of using naturally occurring vaults
- describe providing vaults
- describe incorporating substance into vaults
- describe purifying vaults
- describe administering vaults
- describe vault-like particle
- describe modified MVP
- describe human MVP
- describe Rattus norvegicus MVP
- describe modifications using human and Rattus norvegicus MVP
- describe vault-like particle with modified MVP
- describe adding amino acid sequence to N-terminal of MVP
- describe adding immunogenic peptide to N-terminal of MVP
- describe adding heavy metal binding domain to N-terminal of MVP
- describe adding polynucleotide-binding domain to N-terminal of MVP
- describe adding sensor to N-terminal of MVP
- describe modified VPARP
- describe adding substance-binding domain to VPARP
- describe adding sensor to VPARP
- describe modified TEP1
- describe adding substance-binding domain to TEP1
- describe adding sensor to TEP1
- describe modified vRNA
- describe adding substance-binding domain to vRNA
- describe adding sensor to vRNA
- describe various embodiments of vault-like particles
- provide vault-like particles
- modify MVP with VPARP
- add immunogenic peptide to C-terminal
- add LUC to N-terminal of VPARP
- modify C-terminal of VPARP
- add receptor-binding domain to MVP
- create vault-like particles with receptor-binding domains
- add immunogenic peptide to C-terminal of MVP
- add eukaryotic cell receptor-binding domain to MVP
- add ANT to C-terminal of MVP
- add TAT to C-terminal of MVP
- add αCEA to C-terminal of MVP
- add EGF to C-terminal of MVP
- modify N-terminal and C-terminal of MVP
- add GAL4 to N-terminal of MVP
- add ANT to C-terminal of MVP
- add αCEA to C-terminal of MVP
- add EGF to C-terminal of MVP
- add TAT to C-terminal of MVP
- add GAL4 to N-terminal of MVP
- add MS2 to N-terminal of MVP
- add ANT to C-terminal of MVP
- add αCEA to C-terminal of MVP
- add EGF to C-terminal of MVP
- add TAT to C-terminal of MVP
- add polylysine to N-terminal of MVP
- add ANT to C-terminal of MVP
- add αCEA, EGF, or TAT to C-terminal of MVP
- define vault-like particle
- modify MVP and VPARP
- provide method of preventing damage
- administer vault-like particles
- sequester substance within particles
- provide preferred embodiment
- express particles in eukaryotic organisms
- introduce organisms into contaminated soil
- provide method of delivering substance
- administer particles with substance
- provide preferred substance
- provide method of delivering sensor
- administer particles with sensor
- provide types of sensors
- provide method of detecting signal
- deliver sensor and detect presence
- provide method of making vault-like particles
- create polynucleotide sequences
- produce particles using baculovirus system

## EXAMPLES

### Example 1

- prepare chlamydia-vault-like particles (CVLPs)
- express MOMP-INT construct in sf9 insect cells
- purify vaults by centrifugation and sucrose step gradient
- incorporate MOMP-INT into vaults
- analyze CVLPs by Western blot and silver staining
- describe immunogenic properties of MOMP
- discuss FcR-mediated delivery and Th1 response
- provide background on chlamydial genital infection
- cite previous studies on immunization and protection
- outline experimental design and methods

### Example 2

- immunize mice with CVLPs and analyze protection
- describe immunization protocol and dosage
- analyze bacterial burden and immune response
- discuss Th1 cells and IFNγ+IL-4-CD4+CD3+ cells
- describe flow cytometry analysis
- analyze anti-MoPn antibody response
- discuss IgGc:IgG1 ratio and Th1/Th2 response
- describe IL-17 cells and inflammation
- outline immunization and challenge protocol
- describe C. muridarum growth and purification
- outline experimental procedures and animal care
- describe gel electrophoresis and immunoblotting
- outline immunoblot analysis and detection
- describe isolation of splenocytes and intracellular cytokine analysis
- outline cell culture and stimulation conditions
- describe GolgiPlug treatment and flow cytometry analysis

### Example 3

- evaluate vault-induced endocytosis by dendritic cells
- describe standard uptake assay and FITC-dextran control
- analyze incorporation of GL-vaults by immature BMDCs
- describe flow cytometry analysis and CD11c-PE staining
- outline bone marrow dendritic cell differentiation and purification

### Example 4

- introduce immunization with peptide containing vaults
- measure serum antibody levels in mice
- compare antibody levels between vault immunization and live infection
- analyze antibody specificity using Western blot
- discuss anti-vault antibody development
- test for antibody production against vaults
- describe antibodies and flow cytometry methods
- outline intracellular cytokine staining protocol
- introduce novel vaccine platform for mucosal surfaces
- describe advantages of vault nanoparticles for immunization
- discuss reduction of inflammation and immune-mediated pathology
- analyze MOMP vaults and IgG to MVP
- discuss scope of the invention and incorporated references

